From: Childhood Hodgkin Lymphoma Treatment (PDQ®)
PDQ Cancer Information Summaries [Internet].
Bethesda (MD): National Cancer Institute (US); 2002-.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Table 1. Epidemiology of Hodgkin Lymphoma (HL) Across the Age Spectruma
| Variables | Childhood HL | AYA HL | Adult HL | Older Adult HL | |
|---|---|---|---|---|---|
| Age Range | ≤14 y | 15–35 y | ≥35 y | ≥55 y | |
| Prevalence of HL | 10%–12% | 50% | 35% | ||
| Gender (Male-to-Female Ratio) | 2–3 to 1 | 1 to 1–1.3 to 1 | 1.2 to 1–1 to 1.1 | ||
| Histology: | |||||
| Nodular sclerosing | 40%–45% | 65%–80% | 35%–40% | ||
| Mixed cellularity | 30%–45% | 10%–25% | 35%–50% | ||
| NLPHL | 8%–20% | 2%–8% | 7%–10% | ||
| EBV Associated | 27%–54% | 20%–25% | 34%–40% | 50%–56% | |
| Advanced Stage | 30%–35% | 40% | 55% | ||
| B Symptoms | 25% | 30%–40% | 50% | ||
| Relative Survival: Rates at 5 Years | 94% (age <20 y) | 90% (age <50 y) | 65% (age >50 y) | ||
| AYA = adolescent and young adult; EBV = Epstein-Barr virus; NLPHL = nodular lymphocyte-predominant Hodgkin lymphoma. | |||||
| aAdapted from Punnett et al.[13] | |||||